Who Paid My Doc
Andrea Fraley
Sports Medicine Edmond, OK Medical Doctor
NPI 1487660585 CMS profile 158512
2017 W I 35 Frontage Rd, Suite 130, Edmond, OK 73013
General payments
$6,991
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$575
Through program year 2025, Andrea Fraley of Edmond, OK is reported in the CMS Open Payments database as having received $6,991 across 244 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $575 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $963 | 29 | |
| 2024 | General | $463 | 9 | |
| 2023 | General | $533 | 14 | |
| 2022 | General | $491 | 21 | |
| 2021 | General | $1,429 | 22 | |
| 2020 | General | $868 | 35 | |
| 2019 | General | $2,242 | 114 |
Beside peers
- Andrea Fraley
- Sports Medicine median
- Middle half of Sports Medicine
- National median
In program year 2025, general payments to Andrea Fraley were reported at $963. Among 250 Sports Medicine profiles paid that year, the median was $119 and the middle half received between $39 and $268.
Show as a table
| Year | Andrea Fraley | Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,242 | $125 | $45–$345 | $163 |
| 2020 | $868 | $96 | $33–$311 | $114 |
| 2021 | $1,429 | $113 | $34–$344 | $132 |
| 2022 | $491 | $100 | $35–$293 | $149 |
| 2023 | $533 | $100 | $42–$324 | $160 |
| 2024 | $463 | $139 | $45–$319 | $164 |
| 2025 | $963 | $119 | $39–$268 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 33 drugsPart D claims
6,800
Drug cost
$382,708
Branded share of claims
68.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Belbuca Buprenorphine Hcl | Brand | 127 | $78,509 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 2,027 | $51,464 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 1,530 | $50,412 | |
| Percocet Oxycodone Hcl/Acetaminophen | Brand | 12 | $36,443 | |
| Buprenorphine | Generic | 123 | $26,964 | |
| Lyrica Pregabalin | Brand | 13 | $18,258 | |
| Xtampza Er Oxycodone Myristate | Brand | 44 | $17,992 | |
| Oxycontin Oxycodone Hcl | Brand | 44 | $16,673 | |
| Fentanyl | Generic | 138 | $13,499 | |
| Morphine Sulfate Er Morphine Sulfate | Brand | 534 | $11,690 |
The 10 drugs with the highest cost, of 33 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 33 billing codesPaid by Medicare
$356,669
Medicare patients
808
Services billed
10,039
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 33% | |
| Ischemic heart disease | 33% | |
| Depression | 30% | |
| Chronic kidney disease | 27% | |
| Heart failure | 20% | |
| Osteoporosis | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 157 | 3,665 | $321 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 49 | 436 | $320 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 94 | 278 | $80 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 13 | 23 | $45 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 82 | 322 | $33 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 22 | 74 | $27 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 34 | 60 | $6 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
244 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sports Medicine in Oklahoma
Related records
Sports Medicine in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.